"Over the past five years, Teva has been transformed from a successful generics business into a major global pharmaceutical company. We have achieved double-digit increases in sales and earnings, and have built, acquired or partnered to create new opportunities to support future sustainable growth," Shlomo Yanai, outgoing CEO, Teva, 2012
Teva is a global pharmaceutical company established in Jerusalem in 1901 and specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients.
With operations in over 60 countries and approximately 46,000 employees worldwide, Teva Pharmaceuticals offers the widest range of cost-effective pharmaceuticals, both generic and branded, to millions of consumers, customers and healthcare providers.
Also in 2012, Dr. Jeremy Levin, a former senior executive at Bristol-Myers Squibb (NYSE:BMY), succeeds Shlomo Yanai as CEO.
Products and Acquisitions
2011: Teva acquires large US company Cephalon, and Taiyo, the third largest pharmaceutical company in Japan.
2010: Teva acquires Germany's Ratiopharm, turning Teva into the leading generic pharmaceutical company in Europe.
2008: Teva acquires Barr Pharmaceuticals.
USFDA grants final approval for generic Fosomax tablets.
USFDA grants tentative approval for generic Flomax and Prevaid delayed action capsules.
Teva acquires CoGenesys, a privately held biopharmaceutical company.
2007: USFDA approves generic Dostine and Alprazola tablets.
2006: Teva launches sales of Zoloft and generic Wellbutrin tablets.
Teva acquires IVAX Corporation.
2004: Teva completes the acquisition of US company Sicor, for $3.4 billion, representing the largest-ever such acquisition by an Israeli company to date.
• Net income for 2007 reached $1.952 billion (+5% over 2006).
• Net sales for 2007 were $9.4 billion.
• $18.3 billion annual sales in 2011
*Pictures courtesy of Teva